Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | CEL | P19835 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313489 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL2078510 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL5534476 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL329924 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL5540630 | 0.97 | SIGMAR1 (0.56) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1007113 | 0.95 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1006474 | 0.95 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1007370 | 0.95 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1009023 | 0.95 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 | |
| SCHEMBL1006169 | 0.95 | SIGMAR1 (0.60) | SIGMAR1CYP1A2EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279864-B | Difunctional coumarin oxime ester compound and preparation and application thereof | 湖北固润科技股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-115504896-B | Acrylic formate compound for LED photopolymerization, preparation method and application thereof | 湖北固润科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117986253-A | Blue light red phase pigment and preparation method thereof | 先尼科化工（上海）有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2024078413-A1 | ACRYLOYL FORMATE COMPOUND FOR LED PHOTOPOLYMERIZATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 湖北固润科技股份有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024041569-A1 | ACYLOXYPHOSPHINE OXIME ESTER COMPOUND SUITABLE FOR DEEP CURING OF UV-VIS LED LIGHT SOURCES, METHOD FOR PREPARING SAME, AND USE THEREOF | 湖北固润科技股份有限公司 | 2024-02-29 | — | — | WO | disclosed |
| CN-117142994-A | Amphiphilic polyether alpha-ketone (hetero) arylthioester compound for LED photopolymerization and preparation and application thereof | 湖北固润科技股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117142995-A | Pyruvic acid (hetero) arylthioester compound for LED photopolymerization and preparation and application thereof | 湖北固润科技股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-112094365-B | Photocurable composition containing infrared absorbing photosensitizer, initiator and alkenyl ether and/or oxetane compound | 湖北固润科技股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2022257957-A1 | USE OF γ,δ-UNSATURATED OXIME ESTER COMPOUNDS AS PHOTOINITIATORS | 湖北固润科技股份有限公司 | 2022-12-15 | — | — | WO | disclosed |
| US-11142511-B2 | Coumarin oxime ester compounds, preparation and use thereof | HUBEI GURUN TECHNOLOGY CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-6124507-A | USED IN THE MANUFACTURE OF OLEFIN POLYMERIZATION CATALYSTS WITH PROCATALYSTS HAVING MAGNESIUM, TITANIUM AND HALIDE AS ESSENTIAL COMPONENTS. 1-ETHOXY-2-ALKOXY-4,5,6-OPTIONALLY SUBSTITUTED BENZENES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000009484-A1 | PIPECOLIC ACID DERIVATIVES AND THEIR USE FOR VISION AND MEMORY DISORDERS | GPI NIL HOLDINGS, INC. (US) | 2000-02-24 | — | — | WO | disclosed |
| EP-0926119-A1 | Dialkoxybenzene electron donors | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| CN-1030415-A | Saturated heterocycle carboxamide derivatives and its preparation method | YAMANOUCHI PHARMA CO LTD (JP) | 1989-01-18 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11142511-B2 | Coumarin oxime ester compounds, preparation and use thereof | CBR3, POR, CYP3A4 | SIGMAR1 1668/4885CYP1A2 17/4885EPHX1 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.